Zafgen, Inc. (ZFGN): Price and Financial Metrics

Zafgen, Inc. (ZFGN): $11.88

-2.04 (-14.66%)

POWR Rating

Component Grades













Add ZFGN to Watchlist
Sign Up

Industry: Biotech



in industry

ZFGN Stock Price Chart Interactive Chart >

Price chart for ZFGN

ZFGN Price/Volume Stats

Current price $11.88 52-week high $14.88
Prev. close $1.16 52-week low $0.62
Day low $11.40 Volume 360,258
Day high $14.88 Avg. volume 360,199
50-day MA $0.82 Dividend yield N/A
200-day MA $0.89 Market Cap 445.14M

Zafgen, Inc. (ZFGN) Company Bio

Zafgen Inc. is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. The company was founded in 2005 and is based in Boston, Massachusetts.

ZFGN Latest News Stream

Event/Time News Detail
Loading, please wait...

ZFGN Latest Social Stream

Loading social stream, please wait...

View Full ZFGN Social Stream

Latest ZFGN News From Around the Web

Below are the latest news stories about Zafgen Inc that investors may wish to consider to help them evaluate ZFGN as an investment opportunity.

Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics

Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (ZFGN). The combined, publicly traded clinical-stage biotechnology company will operate under the name Larimar Therapeutics, Inc. and its shares will commence trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol “LRMR.”

Yahoo | May 29, 2020

Zafgen Reports Fourth Quarter and Full Year 2019 Financial Results

Zafgen and Chondrial Therapeutics previously announced a definitive merger agreement Merger creates clinical-stage company focused on the development of novel protein.

Yahoo | March 5, 2020

5 Deep-Value Stocks for 2020

A look at some stocks Benjamin Graham might have liked Continue reading...

Yahoo | December 30, 2019

The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 18) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...

Yahoo | December 19, 2019

Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement

Zafgen, Inc. (ZFGN) and Chondrial Therapeutics, Inc., today announced they have entered into a definitive merger agreement under which Chondrial will become a wholly-owned subsidiary of Zafgen and the stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.

Yahoo | December 18, 2019

Read More 'ZFGN' Stories Here

ZFGN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -13.91%
5-year -86.15%
2022 N/A
2021 N/A
2020 0.00%
2019 -77.58%
2018 7.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6922 seconds.